



**Outcome of using Combined
Modality Treatment for Malignant
Pleural Mesothelioma
(A Retrospective Study)**

Thesis

*Submitted for Partial Fulfillment of Master Degree
in Clinical Oncology and Nuclear Medicine*

By

Eman Samy Ahmed Ismail
M.B.B.Ch

Under Supervision of

Prof. Dr. Atef Youssef Riad

*Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University*

Dr. Mahmoud Abbas El-lithy

*Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University*

*Faculty of Medicine
Ain Shams University
2019*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبِّحْكَ لَا إِلَهَ إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Atef Youssef Riad**, Professor of Clinical Oncology and Nuclear Medicine Faculty of Medicine, Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Mahmoud Abbas El-Lithy**, Ass. Professor of Clinical Oncology and Nuclear Medicine Faculty of Medicine, Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

Eman Samy Ahmed Ismail

List of Contents

Title	Page No.
List of Tables	5
List of Figures	7
List of Abbreviations	11
Introduction	1
Aim of the Study	18
Review of Literature	
▪ Epidemiology	19
▪ Incidence	27
▪ Pathology	31
▪ Diagnosis	46
▪ Treatment	53
Patients and Methods	73
Results	77
Discussion	113
Summary	123
Conclusion and Recommendations	127
References	128
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Current incidence and projected future case load for malignant mesothelioma.....	27
Table (2):	Incidence rates/100.000 population of individual cancer sites in Lower, Middle and Upper Egypt in males.....	29
Table (3):	Incidence rates/100.000 population of individual cancer sites in Lower, Middle and Upper Egypt in females.....	29
Table (4):	Structural and functional differences of the parietal and visceral pleura	33
Table (5):	Grade versus histology.	37
Table (6):	Immunohistochemistry for separating sarcomatoid mesothelioma from squamous and transitional cell carcinoma.	38
Table (7):	Immunohistochemistry to separate epithelioid mesothelioma from adenocarcinoma.....	40
Table (8):	Clinical studies on MPM immunotherapy published in 2017.....	44
Table (9):	Investigations to be considered in patients who are candidates for surgery or multimodal treatment.	47
Table (10):	TNM staging according to the international mesothelioma interest group (IMIG) / Union for international cancer control (UICC).	51
Table (11):	International mesothelioma interest group (IMIG) staging system for malignant pleural mesothelioma.	52

List of Tables Cont...

Table No.	Title	Page No.
Table (12):	Summary of published clinical trials evaluating blocking effects of EGFR.	59
Table (13):	Clinical studies on MPM (Yet to be published).	60
Table (14):	Current investigations in gene trepan.....	61
Table (15):	Parameters to be considered in all patients at presentation/ diagnosis.....	69
Table (16):	Prognostic scoring systems in malignant mesothelioma.....	72
Table (17):	Demographic data distribution of the study group.....	78
Table (18):	Risk factors distribution of the study group.....	81
Table (19):	Presenting symptoms, subtypes of pathology and chemotherapy type.....	84
Table (20):	First line of chemotherapy.....	86
Table (21):	Second line of chemotherapy.....	88
Table (22):	Third line of chemotherapy.	89
Table (23):	Type of surgery.....	89
Table (24):	Outcome distribution of the study group.	91
Table (25):	Median time to progression (TTP) related outcome in all patients.	92
Table (26):	Median overall survival (OS) related outcome in all patients.	93
Table (27):	Time to progression.....	95
Table (28):	Overall survival.....	104

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Bucket shape pottery from Telemark, also found in several other areas in Norway, from the Bronze age to the roman period (400-575AD)	20
Figure (2):	New Cases of Mesothelioma classified as occupational disease according to No. 4105 of the regulation concerning occupational diseases.....	21
Figure (3):	CT scan showing silicosis in a man from the UK who dug tunnels for a living	22
Figure (4):	Prevalence of progressive massive fibrosis in underground coal miners with 25 years or more of exposure in three states of the USA reproduced from Blackley and colleagues, by permission of the American Thoracic society.....	23
Figure (5):	Representation of the normal parietal pleura, the visceral pleura and pleural mesothelioma with the most abundant cell types	32
Figure (6):	Demonstration of 18-fluorodeoxyglucose position emission computed tomography scanning.....	48
Figure (7):	Survival according to type of treatment.....	54
Figure (8):	Chemotherapy regimens used in first, second and third line.....	56
Figure (9):	View through a left thoracotomy.....	62
Figure (10):	Kaplan-Meier survival curve for all patients surviving surgery	64

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (11):	Overall survival as an intention to treat analysis of all patients undergoing surgery for mesothelioma after radiation therapy	65
Figure (12):	Structure definition and dose distribution for one MPM patient	67
Figure (13):	Pie chart age distribution of the study group.....	79
Figure (14):	Pie chart gender distribution of the study group.....	79
Figure (15):	Pie chart residence distribution of the study group.	80
Figure (16):	Pie chart occupation distribution of the study group.	80
Figure (17):	Pie chart co-morbid distribution of the study group.	82
Figure (18):	Pie chart smoking distribution of the study group.	82
Figure (19):	Pie chart subtypes of pathology distribution of the study group.....	84
Figure (20):	Pie chart chemotherapy type distribution of the study group.....	85
Figure (21):	Pie chart 1 st line distribution of the study group.....	87
Figure (22):	Pie chart no. cycles distribution of the study group.	87
Figure (23):	Pie chart type of surgery distribution of the study group.	90
Figure (24):	Pie chart outcome distribution of the study group.	91

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (25):	Median of time to progression in all patients.	92
Figure (26):	Median of overall survival in all patients.	93
Figure (27):	TTP between age category.	97
Figure (28):	TTP based on gender category.	97
Figure (29):	TTP based on residence.	98
Figure (30):	TTP based on occupation.	98
Figure (31):	TTP between co-morbid.	99
Figure (32):	TTP between smoking.	99
Figure (33):	TTP between symptoms.	100
Figure (34):	TTP between subtypes of pathology.	100
Figure (35):	TTP between chemotherapy types.	101
Figure (36):	TTP between 1 st line of chemotherapy.	101
Figure (37):	TTP between response to first line chemotherapy.	102
Figure (38):	TTP between type of surgery.	102
Figure (39):	OS between age (years).	106
Figure (40):	OS between gender.	106
Figure (41):	OS between residences.	107
Figure (42):	OS between occupations.	107
Figure (43):	OS between co-morbidities.	108
Figure (44):	OS between smoking.	108
Figure (45):	OS between symptoms.	109
Figure (46):	OS between subtypes of pathology.	109
Figure (47):	OS between chemotherapy types.	111
Figure (48):	OS between 1 st line of chemotherapy.	111

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (49):	OS between response to1 st line chemotherapy.	112
Figure (50):	OS between types of surgery.....	112

List of Abbreviations

Abb.	Full term
ARD.....	Asbestos Related Disease
BFGF	Basic Fibroblast Growth Factor
CT	Computed Tomography
DNA	Deoxyribonucleic Acid
EGFR	Epidermal Growth Factor Receptor
EPP	Extra Pleural Pneumonectomy
FDA	Food and Drug Administration
FISH	Flourescence In Situ Hybridization
FNAC	Fine Needle Aspiration Cytology
Gy	Grey
IMRT	Intensity-Modulated Radiation Therapy
MPM.....	Malignant Pleural Mesothelioma
MRI.....	Magnetic Resonance Imaging
PD	pleurectomy/Decortication
PDGF	Platelet-derived Growth Factor
PET	Positron Emission Tomography
PS.....	Performance Status
VATS.....	Video-assisted Thoracoscopic Surgery
VEGFR	Vascular Endothelial Growth Factor Receptor
WHO.....	World Health Organization

INTRODUCTION

Malignant mesothelioma (MM) is a relatively rare cancer arising from the mesothelial lining of pleura as well as the peritoneal cavities, tunica vaginalis, and pericardium (*Price and Ware, 2005*).

Histological subtypes of malignant pleural mesothelioma (MPM) include epithelioid (about 60%) and non-epithelioid (about 40%) variants; non-epithelioid variants include subtypes of spindle, sarcomatoid, desmoplastic, fibrous, biphasic, and not otherwise specified (*Robinson, 2012*).

Malignant pleural mesothelioma (MPM) is caused primarily by inhalation of asbestos (about 80% of cases) Its pathogenesis is closely associated with iron overload and oxidative stress in mesothelial cells. (*Robinson, 2012*).

Upon fiber exposure, mesothelial cells accumulate fibers simultaneously with iron, which either performs physical scissor function or catalyzes free radical generation, leading to oxidative DNA damage such as strand breaks and base modifications, followed by activation of intracellular signaling pathways and this is how asbestos cause indirect genetic damage in addition to its direct damage (*Kamp et al., 1992*).

The incidence of MPM revealed a gradual increase in number of cases in Europe over the last 40 years with male: female ratio has changed from 1:1 to 4:1 and it is expected that

the incidence of MPM will continue to rise till approximately 2020 (*Galateau-Salle et al., 2014*)

The relatively late discovery of most cases is due to the long interval between exposure of asbestos and development of mesothelioma with latency period of 30 to 45 years. So, because of its carcinogenic property, the use of asbestos has been banned in many developed countries, but some developing countries such as China and India still permit its usage (*Sezer et al., 2014*)

The incidence in Egypt is expecting to rise in the following years, the total estimated cases are (207, 238, 456) in (2020, 2025, 2050) respectively (*Ibrahim et al., 2014*).

Another cause that may account for the development of MPM is Exposure to mineral fibers as in house hold s though it's quite rare (*Ronald et al., 2018*).

Also there are reports that suggest that ionizing radiation may also cause mesothelioma, such as in patients previously treated with mantle radiation for Hodgkin lymphoma (*Xu et al., 2015*).

Genetic factors may also play a role in MPM, with some families carrying a germ line mutation in the BRCA1 Associated Protein 1 (BAP1) gene which increase the incidence of MPM (*Ohar et al., 2016*).

Smoking is not a risk factor for mesothelioma, however patients who smoke and have been exposed to asbestos are at increased risk for lung cancer. In addition, patients who smoke should be encouraged to quit because smoking impedes treatment (e.g., delays wound healing after surgery) (*Mossman et al., 2011*).

Symptoms that patients with suspected MPM often have include dyspnea and chest pain; they may also have pleural effusion, fatigue, insomnia, cough, chest wall mass, loss of appetite, and weight loss (*Dyer et al., 2013*).

In patients with recurrent pleural effusion and/or pleural thickening, the recommended initial evaluation for suspected MPM includes:

1. Computed Tomography (CT) of the chest with contrast.
2. Thoracentesis for cytologic assessment of the effusion
3. Pleural biopsy (eg, thoracoscopic biopsy, preferred)

(*van Zandwijk et al., 2013*).

However, cytologic samples are often negative even when patients have MPM (*Paintal et al., 2013*). Fine-needle aspiration (FNA) is not recommended for diagnosis (*van Zandwijk et al., 2013*). Talc pleurodesis or pleural catheter may be needed for management of pleural effusion (*Hunt et al., 2012*). Soluble mesothelin-related peptide (SMRP) levels may

also be assessed, and these levels may correlate with disease status (*Hollevoet et al., 2012*).

Calretinin, WT-1, D2-40, and cytokeratin (CK) 5/6 are useful immunohistochemical markers for the diagnosis of MPM, as are markers that typically are positive in pulmonary adenocarcinoma and negative in mesothelioma (*Henderson et al., 2013*).

Because MPM is often diagnosed late, it has a poor prognosis with five-year survival is still approximately 8 %. It occurs mainly in older men (median age at diagnosis, 72 years) who have been exposed to asbestos, although it occurs decades after exposure (20-40 years later) (*Taioli et al., 2015*).

Median survival for untreated malignant pleural mesothelioma is usually less than 1 year, survival figures must always be interpreted with caution and be compared with the average survival of nine months with supportive care alone. (*Milano and Zhang, 2010*).

Patients that are candidate for multimodality treatment are selected according to: the clinical stage (I-III) and good performance (*de Perrot et al., 2009*).

1- The surgical goal of MPM is cyto reductive surgery to achieve macroscopic complete resection by removing all visible or palpable tumors (*Sugarbaker et al., 2011*).